On the other hand, seldom reports directly addressed the relationship between gastrointestinal tract tumor risks and GLP-1 receptor agonists and SGLT2 inhibitors use, which tumors accounted for 26% of the global cancer incidence and 35% of all cancer-related deaths[11]. This evidence concerns the gene GLP1R and cancer.